康莱特注射液联合SOX方案(替吉奥+奥沙利铂)治疗晚期(ⅢB~Ⅳ期)胃癌患者的临床效果

Clinical effect of Kanglaite injection combined with SOX regimen(teggio+oxaliplatin)in the treatment of patients with advanced gastric cancer(stage ⅢB-Ⅳ)

目的观察康莱特注射液联合SOX方案(替吉奥+奥沙利铂)治疗晚期(ⅢB~Ⅳ期)胃癌患者的临床效果。方法将71例晚期(ⅢB~Ⅳ期)胃癌患者随机分为对照组(n=34)和观察组(n=37)。对照组予以SOX方案治疗,观察组在对照组基础上给予康莱特注射液治疗。比较两组的临床疗效、CA199、CEA水平、生活质量评分及不良反应发生情况。结果两组的DCR无显著差异(P>0.05)。治疗后,两组的CA199、CEA水平均较治疗前降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的情绪功能、社会功能及总体健康状况评分均高于治疗前,且观察组的情绪功能及社会功能评分高于对照组,差异具有统计学意义(P<0.05)。观察组的肝功能损害总发生率低于对照组(P<0.05)。结论康莱特注射液联合SOX方案治疗晚期胃癌患者,能够降低CA199、CEA水平,改善患者的生存质量,且安全性高。

Objective To observe the clinical effect of Kanglaite injection combined with SOX regimen(teggio+oxaliplatin)in the treatment of patients with advanced gastric cancer(stage ⅢB-Ⅳ).Methods Seventy-one patients with advanced gastric cancer(stage ⅢB-Ⅳ)were randomly divided into control group(n=34)and observation group(n=37).The control group was treated with SOX regimen,and the observation group was treated with Kanglaite injection on the basis of the control group.The clinical efficacy,CA199 and CEA levels,quality of life scores and adverse reactions were compared between the two groups.Results There was no significant difference in DCR between the two groups(P>0.05).After treatment,the levels of CA199 and CEA in the two groups were lower than those before treatment,those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of emotional function,social function and overall health status of the two groups were higher than those before treatment,the scores of emotional function and social function of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).The total incidence of liver function damage in the observation group was lower than that in the control group(P<0.05).Conclusion Kanglaite injection combined with SOX regimen in the treatment of patients with advanced gastric cancer can reduce the levels of CA199 and CEA,and improve the quality of life of patients,with high safety.